Skip to main content

Table 3 Time course of changes in serum beta-cell function during antiviral treatment of patients with SVR

From: The association of hepatitis c virus infection status with serum glucose levels

 

Baseline

End-Rx

FU-24

P1 value

P2 value

FBG (mmol/l)

5.41 ± 0.81

4.60 ± 0.68

5.09 ± 0.83

< 0.001

0.002

FINS (μU /ml)

8.30 ± 3.80

7.88 ± 4.15

8.18 ± 3.99

0.007

0.806

FCP (nmol/l)

0.92 ± 0.25

0.72 ± 0.26

0.78 ± 0.27

< 0.001

0.000

HOMA-IR

2.00 ± 1.02

1.62 ± 0.94

1.86 ± 1.20

< 0.001

0.052

HOMA-β

104.5 ± 71.9

183.7 ± 127.8

134.3 ± 108.6

< 0.001

0.01

ISI

−3.70 ± 0.45

−3.45 ± 0.54

−3.60 ± 0.52

< 0.001

0.05

  1. Data are expressed as mean ± SD;
  2. FBG fasting blood glucose, FINS fasting insulin, FCP fasting C peptide, HOMA-IR homeostasis model assessment for insulin resistance, HOMA-β homeostasis model assessment for beta-cell function, ISI insulin sensitivity index, Rx treatment; FU-24, follow up at 24 weeks post treatment
  3. P1, value for comparison of baseline and end-Rx values; P2, value for comparison of baseline and FU-24 values